Breast Carcinoma clinical trials

Explore recruiting breast carcinoma clinical trials.

Recruiting breast carcinoma studies right now

Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record

Also recruiting in Europe

Breast Carcinoma trials registered in the EU Clinical Trials Information System (CTIS). These are outside the "near me" matcher above - open a study for full details.

Multimodal Imaging with FAPI-PET/MRI in Breast Carcinoma-In-Situ for Detection of occult Invasive cancer (MI-CISDIR)

Germany

Therapeutic exploratory (Phase II) EU CTIS Study details

RESTORING SENSITIVITY TO IMMUNOTHERAPY IN ADVANCED TRIPLE NEGATIVE BREAST CANCER EXPLOITING CERALASERTIB PRIMING FOLLOWED BY COMBINED DURVALUMAB/NAB-PACLITAXEL: THE ATRiBRAVE TRIAL

Italy

Therapeutic exploratory (Phase II) EU CTIS Study details

Permanence of Indocyanine Green in axillary lymph nodes three weeks after subdermal injection in patients with Breast Carcinoma and metastatic lymph nodes: The FLUO Trial

Italy

Therapeutic exploratory (Phase II) EU CTIS Study details

HER2 molecular imaging with 89Zr-trastuzumab PET/CT as a predictive biomarker for antibody-drug conjugate sequencing in patients with advanced HER2-positive breast cancer

Belgium, Netherlands

Therapeutic exploratory (Phase II) EU CTIS Study details

HER2 molecular imaging with 89Zr-trastuzumab PET/CT as a predictive biomarker for antibody-drug conjugate sequencing in patients with advanced HER2-positive breast cancer

Belgium

Therapeutic exploratory (Phase II) EU CTIS Study details

Phase II neoadjuvant study evaluating capivasertib plus fulvestrant vs fulvestrant in patients with primary high-risk lobular breast cancer- LOBSTER

Germany

Therapeutic exploratory (Phase II) EU CTIS Study details

Breast Carcinoma trials by city

Breast Carcinoma in Toronto Breast Carcinoma in Vancouver Breast Carcinoma in Montreal Breast Carcinoma in Calgary Breast Carcinoma in Edmonton Breast Carcinoma in Ottawa Breast Carcinoma in Winnipeg Breast Carcinoma in Quebec City Breast Carcinoma in Hamilton Breast Carcinoma in Kitchener Breast Carcinoma in London Breast Carcinoma in Halifax Breast Carcinoma in New York Breast Carcinoma in Los Angeles Breast Carcinoma in Chicago Breast Carcinoma in Houston

Other conditions

Obesity Type 2 diabetes Type 1 diabetes Prediabetes Weight loss Metabolic syndrome High cholesterol High triglycerides High blood pressure PCOS Hypothyroidism Thyroid disease Gout Fatty liver disease (NAFLD/NASH) Heart failure Coronary artery disease Atrial fibrillation Stroke Stroke recovery Peripheral artery disease Pulmonary hypertension Deep vein thrombosis Chronic kidney disease Diabetic kidney disease